# Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients

> **NCT04475120** · PHASE2,PHASE3 · COMPLETED · sponsor: **University of Rome Tor Vergata** · enrollment: 92 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** liposomal lactoferrin
- **DRUG:** SOC therapy

## Key facts

- **NCT ID:** NCT04475120
- **Lead sponsor:** University of Rome Tor Vergata
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-15
- **Primary completion:** 2020-07-02
- **Final completion:** 2020-07-02
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2021-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04475120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04475120, "Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04475120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*